Radiotherapy (RT) is a cornerstone in the management of advanced stage III and stage IV

non-small-cell lung cancer (NSCLC) patients. Despite international guidelines, clinical practice remains

heterogeneous. Additionally, the advent of stereotactic ablative RT (SABR) and new systemic treatments

such as immunotherapy have shaken up dogmas in the approach of these patients. This review will focus on

palliative thoracic RT for NSCLC but will also discuss the role of stereotactic radiotherapy, endobronchial

brachytherapy (EBB), the interest of concomitant treatments (chemotherapy and immunotherapy), and the

role of RT in lung cancer emergencies with palliative intent.